The author concurs with Bola's conclusion that ''a categorical prohibition of medication-free research in early episode schizophrenia on the ethical grounds of harm to human subjects should probably be reconsidered'' on a case-by-case basis. The point that informed choice is rarely considered in the informed consent process is made. Several recommendations are made on how to augment the informed consent process and enhance the decision making of research participants.
Key words: informed choice/informed consent/ risk-benefit/decisionally impaired/greater than minimal risk research Let me start my commentary with my conclusion: I agree with Dr. Bola's conclusion that ''a categorical prohibition of medication-free research in early episode schizophrenia on the ethical grounds of harm to human subjects should probably be reconsidered.'' I would also add that, as the saying goes, the devil (of conducting such research) is in the details.
In the late 1990s the director of the National Institute of Mental Health convened a workshop on medication discontinuation, use of placebo, and symptom provocation. This was, in part, a response to a National Bioethics Advisory Council report that raised doubts about the use of placebo, symptom provocation, and medication discontinuation in research with individuals who could be considered decisionally impaired as a class, inter alia, persons with serious mental illness.
This punctuated a period of intense debate among psychiatric researchers, advocacy groups, and ethicists, self-appointed and otherwise, as to whether seriously mentally ill persons are able to consent to participate in greater than minimal risk research. Among other actions, an Institute of Medicine study was commissioned, and a report was issued. The Office of Human Research Protection was created out of the Office for Protection from Research Risks to raise the visibility of protecting human subjects in research funded by the Department of Health and Human Services.
Despite years of inquiry, scrutiny, and debate, few scandals have been uncovered. While undoubtedly painful, the beneficial results of this period of turmoil in the research community have lead to a heightened awareness on the part of researchers of the need to continue to conduct research ethically and the knowledge that ethics in research is in constant evolution. There is a deeper, more sophisticated understanding of the issues surrounding what constitutes decisional incapacity and the process of informed consent. Contrary to what some individuals and groups maintained, it appears that persons who are seriously mentally ill can choose to participate in research out of altruism and are capable of giving informed consent.
Notwithstanding the above, individuals-and their families * -experiencing first-or second-episode schizophrenia deserve some special consideration from researchers who are conducting medication-free research and from institutional review boards (IRBs) who approve such research. It is abundantly clear that while tremendous strides have been made in understanding schizophrenia, what remains unknown about the illness is still vastly greatly than what is known. This certainly means that there may be a need to conduct research using protocols including short-duration, medication-free intervals. With adequate consent procedures, good risk management, rescue plans, and provisions for treatment if needed (or desired, should the participant have a change of heart about continuing in the study), and considering the need for knowledge about a serious, disabling, and sometimes fatal disorder, protocols incorporating 1 To whom correspondence should be addressed; e-mail: jmcnulty@nami.org. *I encourage the involvement of families in research projects, but the nature of the illness and family relationships often prevent this. In this event, use of an outside consent monitor or trusted (by the potential participant) third party would be advisable. This is undoubtedly onerous but nonetheless a reasonable step in research designated as higher than minimal risk. Videotaping the consent process (with consent) for later review by an independent panel is also reasonable in research that has the potential for being highly controversial. 2006 short-term medication-free periods should be considered on a case-by-case basis.
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In the first or second episode of schizophrenia, the potential research participant and family are unlikely to have a full appreciation of the difficulties that they are likely to experience as a result of the impact of the illness, in every dimension of life. It is simply not possible for a researcher to account for all the variables to a potential research participant or family member, given the role that experience and individual variations of schizophrenia will play in their lives. In fact, attempting to do so when individuals have no way to put the information in any context can lead to paralysis in decision making and makes informed choice, and therefore informed consent, much more unlikely.
Playing fair with potential research participants and families requires a concise explanation of the risks and benefits of the protocol and assurance that the research protocol has been designed in such a way as to minimize participant risk. It is essential that a good rescue plan be in place. Also of critical importance: it should be clear that the research project is asking an important scientific question about schizophrenia and can reasonably be expected to add to the body of knowledge about schizophrenia. Unfortunately, much of the energy expended in trying to ensure informed consent has focused on the consent form itself. In many instances IRB members are unable to understand the complexities contained in these forms, let alone the concerns of research participants or families. What most potential research subjects and their families want to know is contained in the answers to the following questions (which should be seen as augmenting the consent form and process, not replacing them):
What scientific/clinical question does the protocol propose to answer? Why is it important? Why is the question important enough for me to consider postponing the medication component or portion of the treatment for a short duration (note that clinical care/treatment will be ongoing during the medicationfree period)? Is the protocol designed in such a way that it is likely add to the essential body of knowledge about schizophrenia, its causes and treatments, regardless of whether the study hypothesis is proven or disproven? Do the investigators have the credentials to be able to successfully carry the study to its conclusion? What are the risks to me? What is the most likely adverse consequence of delaying medication? Will it make the illness worse? Do you have plan in place to minimize the risk? A rescue strategy? Will I personally benefit from the research? Can I withdraw from the study without any penalties? If I don't participate in the study, what are my treatment options? Would you ask your son/daughter/mother/father to participate in this study? When you know the results of the research, will you tell me?
Researchers should address these questions as simply and directly as possible, avoiding jargon as much as possible. Researchers should also be direct about the difference between research and treatment, dealing with the therapeutic misconception preemptively. If it is unlikely that the participant will benefit directly from the research, say so. All of this information is typically buried in a tediously (particularly if one is experiencing psychosis) long consent form, which very few potential participants actually read.
Researchers have been focused on the informed consent document, understandably so, since law and regulation demand it. What consumers and families want and need, however, is the ability to make an informed choice, which is necessary for giving informed consent. Only specific information and knowledge make this possible. It is critical that researchers provide this information and knowledge to us and that they do so in ways that engage the prospective participants and families in the process of becoming an informed decision maker. The best way to make certain that necessary research with higher degrees of risk will come to be less controversial is to ensure that participants are seen as making rational, informed choices because they understand the risks and uncertainties, both of their illness and of the research in which they are being asked to participate.
